Loading...
•
Mar 31, 2024
Bioxcel Therapeutics Q1 2024 Earnings Report
Reported first quarter 2024 financial results and advanced TRANQUILITY and SERENITY program plans.
Key Takeaways
BioXcel Therapeutics reported its Q1 2024 financial results, highlighting a 182% increase in IGALMI net revenue compared to the same period last year, driven by increasing demand and new customer orders. The company is advancing its TRANQUILITY and SERENITY programs and strengthened its balance sheet with a $25 million registered direct offering.
Advanced TRANQUILITY and SERENITY program plans for two pivotal Phase 3 trials to expand BXCL501 market potential in acute treatment of agitation.
Strengthened intellectual property portfolio for BXCL501 with grant of two new patents, in Japan and the U.S.
Completed $25 million registered direct offering.
IGALMI net revenue increased 182% compared to Q1 2023.
Revenue by Segment
Forward Guidance
BioXcel Therapeutics is focused on advancing and expanding its agitation portfolio, with plans for Phase 3 registrational programs for BXCL501 and expansion into the at-home setting and Alzheimer’s-related agitation.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...